Pharmaceutical Manufacturing – Loperamide Hydrochloride

The contract involves the manufacturing of FDA-compliant Loperamide Hydrochloride dosage units for integration into the government supply chain, with potential use by prime or tier-2 suppliers under Defense Logistics Agency agreements. Production must adhere to strict pharmaceutical quality standards to meet regulatory requirements for federal distribution, ensuring the drug's safety, efficacy, and consistency for intended government applications. The work is classified under NAICS code 325412 for pharmaceutical preparation manufacturing and is structured as a subcontract tied to a larger DLA procurement initiative, specifically linked to contract SPE2DX25D9900 and delivery order SPE2DP26F7539. All manufacturing activities are expected to align with the defense supply chain's operational needs, likely supporting medical readiness or emergency response protocols where Loperamide Hydrochloride is required. While the place of performance and point of contact details are not specified, the contract underscores compliance with federal pharmaceutical regulations and the importance of reliable, scalable production capacity to serve DOD and allied agencies. The posting date of July 14, 2026, indicates this is a forward-looking procurement, suggesting advanced planning for sustained supply needs beyond immediate operational demands.